Monograph index
- Liraglutide and the daily GLP-1 schedule Saxenda’s labeled daily escalation to 3 mg, the 16-week adult stopping rule, and how a daily injection differs from weekly semaglutide or tirzepatide.
- Oral options and compounded GLP-1 products How Wegovy tablets differ from Rybelsus, and what FDA has said about compounded, unapproved, and salt-form GLP-1 products.
- Semaglutide doses and indications, as labeled Wegovy injection, Wegovy tablets, Ozempic, and Rybelsus — what each label says about dose, missed doses, and trial results.
- Tirzepatide doses and indications, as labeled Zepbound and Mounjaro schedules, SURMOUNT-1 results, missed-dose rules, and the warnings the labels share with GLP-1 agonists.
- Which GLP-1 medicines are approved for what A label-first map of semaglutide, tirzepatide, and liraglutide products, and the indications those brands do not share.